CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 77 enrolled
Drug / intervention
WB007 0.05% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04149899
NCT04149899Phase 2Completed
CompareCT.gov

A Phase 1/2a Assessment of WB007 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

Bausch & Lomb Incorporated·interventional·Posted Nov 4, 2019·Updated Mar 27, 2025

In Brief

A Phase 2 clinical trial evaluating WB007 0.05%, WB007 0.15%, and 2 other interventions for Glaucoma, Primary Open Angle and Ocular Hypertension. Completed, enrolled 77 participants across 1 site.

Detailed Summary

The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study. Part 1 was a 3-period dose escalation that evaluated 3 concentrations of WB007 ophthalmic solution following a single dose in one eye. Part 2 was a randomized, double-masked, parallel comparison that evaluated two concentrations of WB007 (selected based on Part 1 results) in both eyes compared with timolol 0.5% for 14 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Primary Open Angle, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedNov 4, 2019
Enrollment StartNov 14, 2019
Primary CompletionJan 31, 2021
Study CompletionDec 14, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.7 years ago

Interventions

WB007 0.05%drug

WB007 Ophthalmic Solution 0.05%

WB007 0.15%drug

WB007 Ophthalmic Solution 0.15%

WB007 0.4%drug

WB007 Ophthalmic Solution 0.4%

Timolol 0.5%drug

Timolol Maleate 0.5% Ophthalmic Solution